Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SABS
$3.74
$
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Beta
0.596
Average Volume
Market Cap
Last Dividend
CIK
0001833214
ISIN
US78397T2024
CUSIP
78397T103
CEO
Samuel J. Reich
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
63
IPO Date
2021-02-09
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of “Moderate Buy” from Analysts | SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation | Defense World | 2026-02-17 01:54:48 |
| Head to Head Analysis: SAB Biotherapeutics (NASDAQ:SABS) versus Viking Therapeutics (NASDAQ:VKTX) | Viking Therapeutics (NASDAQ: VKTX - Get Free Report) and SAB Biotherapeutics (NASDAQ: SABS - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of current | Defense World | 2026-02-05 02:36:54 |
| SAB BIO to Participate in Upcoming Investor Conferences | MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February: | GlobeNewsWire | 2026-02-04 09:00:00 |
| SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director | David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D. | GlobeNewsWire | 2026-01-07 08:00:00 |
| SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference | MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company's CEO Samuel J. Reich will present at the 44th Annual J.P. | GlobeNewsWire | 2026-01-06 08:00:00 |
| First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D | Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAF ety and E fficacy of human anti-thymocyte immuno G lob U lin SAB-142 AR resting progression of type 1 D iabetes (SAFEGUARD) clinical trial. SAB-142 is in development as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach to treat stage 3 T1D by delaying the progression of disease. | GlobeNewsWire | 2025-12-18 08:00:00 |
| SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D | Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetes Phase 2b SAFEGUARD trial underway and recruiting at multiple sites around the world MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced positive, confirmatory data from a Phase 1 trial of SAB-142 in a single- and multiple-ascending dose among healthy volunteers (n=62), including a re-dosed cohort, and T1D patients (n=6). The study met its primary objectives to establish a safety profile and characterize pharmacodynamic activity enabling SAB-142 to advance to Phase 2b clinical development in the SAF ety and E fficacy of human anti-thymocyte immuno G lob U lin SAB-142 AR resting progression of type 1 D iabetes (SAFEGUARD) clinical trial, now underway. | GlobeNewsWire | 2025-12-17 08:00:00 |
| SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management | MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore. | GlobeNewsWire | 2025-12-08 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| SC 13G | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| EFFECT | 2026-01-07 | 2026-01-08 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 3 | 2026-01-07 | 2026-01-07 | View Filing |
| 3 | 2026-01-07 | 2026-01-07 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| S-3 | 2025-12-29 | 2025-12-30 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| S-8 | 2025-12-15 | 2025-12-15 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-13 | View Filing |
| 424B3 | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G | 2025-10-03 | 2025-10-03 | View Filing |
| SC 13D | 2025-10-03 | 2025-10-03 | View Filing |
| SC 13G | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| 4 | 2025-10-01 | 2025-10-01 | View Filing |
| EFFECT | 2025-10-01 | 2025-10-01 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| S-3/A | 2025-09-22 | 2025-09-22 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| S-3 | 2025-09-02 | 2025-09-02 | View Filing |
| DEF 14A | 2025-08-29 | 2025-08-29 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| PRE 14A | 2025-08-19 | 2025-08-19 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| D | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 8-K | 2025-07-21 | 2025-07-21 | View Filing |
| 8-K | 2025-07-17 | 2025-07-17 | View Filing |
| DEF 14A | 2025-06-02 | 2025-06-02 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| S-8 | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K | 2025-03-31 | 2025-03-28 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-01-28 | 2025-01-28 | View Filing |
| 4 | 2024-12-31 | 2024-12-31 | View Filing |
| 10-Q | 2024-11-06 | 2024-11-06 | View Filing |
| 4 | 2024-11-05 | 2024-11-05 | View Filing |
| 8-K | 2024-09-09 | 2024-09-09 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| S-8 | 2024-08-12 | 2024-08-12 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 3 | 2024-07-31 | 2024-07-31 | View Filing |
| 8-K | 2024-07-31 | 2024-07-31 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 4 | 2024-07-17 | 2024-07-17 | View Filing |
| 8-K | 2024-06-27 | 2024-06-27 | View Filing |
| 3 | 2024-06-24 | 2024-06-24 | View Filing |
| 8-K | 2024-05-31 | 2024-05-30 | View Filing |
| DEF 14A | 2024-05-30 | 2024-05-30 | View Filing |
| 8-K | 2024-05-21 | 2024-05-21 | View Filing |
| 10-Q | 2024-05-20 | 2024-05-20 | View Filing |
| NT 10-Q | 2024-05-15 | 2024-05-15 | View Filing |
| 3 | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-08 | 2024-05-07 | View Filing |
| 8-K | 2024-04-15 | 2024-04-15 | View Filing |
| 8-K | 2024-03-29 | 2024-03-29 | View Filing |
| 10-K | 2024-03-29 | 2024-03-28 | View Filing |
| 8-K | 2024-03-08 | 2024-03-08 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Liquidity Sweep Strategy | 23.22% | 1 | 1 | 0.89 | 1.13 | 14.57 |
| Pivot Points Strategy | 18.37% | 0.94 | 11 | 0.66 | 0.69 | 9.44 |
| Adaptive Wave | 18.22% | 1 | 1 | 0.77 | 1.02 | 9.57 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxx | xxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |